Skip to content

Xencor

US · XNCR #2825 by market cap Listed 1970
33.26 -0.75 -2.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:51

About Xencor

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.

Founded
1997
CEO
Dr. Bassil I. Dahiyat, PhD.
Employees
260
Headquarters
Pasadena, California, United States of America
Fiscal year end
12-31
Website
xencor.com

Company profile

Exchange
US
Symbol
XNCR
Market-cap rank
#2825
Listing date
1970-01-01
Market cap
2.50B
Float cap
1.86B
Shares out
75.04M
Float shares
55.81M

Sectors & themes

Biotechnology Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:51:50 · For reference only, not investment advice and not tailored to your situation.

Xencor discussion 0 comments

Add a comment